“We are excited to have Dr. Terry Jones and the team at J&S Studies join this important study. They are top clinical researchers in the field of dermatology, and specifically onychomycosis.” ~ Mark Taylor, Hallux Inc. CEO

LAGUNA HILLS, Calif. (PRWEB)
July 07, 2022

Hallux Inc., a clinical stage pharmaceutical company, today announced that J&S Studies Inc. of College Station, Texas has begun screening patients for enrollment into HSG-201, its 52 week clinical study evaluating Hallux Subungual Gel (HSG) for the treatment of onychomycosis (toenail fungus).

Hallux CEO Mark Taylor said, “We are excited to have Dr. Terry Jones and his team at J&S join this important study. Dr. Jones and J&S are top clinical researchers in the field of dermatology, and specifically onychomycosis. It is important to evaluate the product and subungual topical procedure in a podiatric setting and a dermatology setting as the patient populations can be slightly different. As Sponsor, we are fortunate to have clinical experts like Dr. Jones and Dr. Lewis Freed of OrthoArizona follow our Phase 2 protocol to treat mycologically confirmed onychomycosis patients in their respective communities.

About Hallux

Hallux Inc. is a clinical-stage pharmaceutical company focused on developing a new dosage form and route of administration for treating onychomycosis (toenail fungus). Hallux’s goal is to provide high effectiveness and safety for chronic onychomycosis patients around the world. The company’s investigational approach with its new subungual topical terbinafine drug candidate HSG is to demonstrate safety and high efficacy by means of administration directly and selectively to the site of the nail bed site infection.

Share article on social media or email: